FDA Updates Enzalutamide Label in mCRPC

The FDA has updated the label for enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC) to include new data from the phase II TERRAIN study, according to the codevelopers of the androgen receptor inhibitor, Astellas and Pfizer. In the trial, enzalutamide reduced the risk of radiographic progression or death by 40% compared with bicalutamide. The median radiographic progression-free survival (rPFS) was improved by 6.1 months with … (leggi tutto)